دورية أكاديمية
Pretreatment with Yeast-Derived Complex Dietary Polysaccharides Suppresses Gut Inflammation, Alters the Microbiota Composition, and Increases Immune Regulatory Short-Chain Fatty Acid Production in C57BL/6 Mice.
| العنوان: | Pretreatment with Yeast-Derived Complex Dietary Polysaccharides Suppresses Gut Inflammation, Alters the Microbiota Composition, and Increases Immune Regulatory Short-Chain Fatty Acid Production in C57BL/6 Mice. |
|---|---|
| المؤلفون: | Gudi R; Department of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA., Suber J; Department of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA., Brown R; Department of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA., Johnson BM; Department of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA., Vasu C; Department of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA. |
| المصدر: | The Journal of nutrition [J Nutr] 2020 May 01; Vol. 150 (5), pp. 1291-1302. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 0404243 Publication Model: Print Cited Medium: Internet ISSN: 1541-6100 (Electronic) Linking ISSN: 00223166 NLM ISO Abbreviation: J Nutr Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : [New York, NY] : Elsevier Original Publication: 1928-1933 : Springfield, Ill. : C. C. Thomas |
| مواضيع طبية MeSH: | Colitis/*prevention & control , Gastrointestinal Microbiome/*drug effects , Polysaccharides/*administration & dosage , Saccharomyces cerevisiae/*chemistry , beta-Glucans/*administration & dosage, Animals ; Colitis/chemically induced ; Colitis/immunology ; Dextran Sulfate/pharmacology ; Fatty Acids, Volatile/analysis ; Feces/chemistry ; Feces/microbiology ; Female ; Forkhead Transcription Factors/genetics ; Gene Knock-In Techniques ; Green Fluorescent Proteins/genetics ; Immunity/drug effects ; Intestines/immunology ; Male ; Mice ; Mice, Inbred C57BL |
| مستخلص: | Background: β-Glucans (BGs), a group of complex dietary polysaccharides (CDPs), are available as dietary supplements. However, the effects of orally administered highly purified BGs on gut inflammation are largely unknown. Objectives: The aim of this study was to investigate the impact of orally administering highly purified, yeast-derived BG (YBG; β-1,3/1,6-d-glucan) on susceptibility to colitis. Methods: Eight-week-old C57BL/6 (B6) mice were used in a series of experiments. Experiment (Expt) 1: male and female mice were treated every day, for 40 d, with saline (control) or 250 μg YBG, followed by 2.5% (wt:vol) dextran sulfate sodium (DSS) in drinking water during days 30-35; and colitis severity and intestinal immune phenotype were determined. Expt 2: female B6 mice were treated with saline or YBG for 30 d and intestinal immune phenotype, gut microbiota composition, and fecal SCFA concentrations were determined. Expt 3: female B6 mice were treated as in Expt 2, given drinking water with or without antibiotics [Abx; ampicillin (1 g/L), vancomycin (0.5 g/L), neomycin (1 g/L), and metronidazole (1 g/L)] during days 16-30, and gut immune phenotype and fecal SCFA concentrations were determined. Expt 4: female B6 Foxp3-green fluorescent protein (-GFP) reporter mice were treated as in Expt 3, and intestinal T-regulatory cell (Treg) frequencies and immune phenotypes were determined. Expt 5: female mice were treated as in Expt 1, given drinking water with or without antibiotics during days 16-40, and colitis severity and intestinal cytokine production were determined. Results: Compared with controls, the YBG group in Expt 1 exhibited suppressive effects on features of colitis, such as loss of body weight (by 47%; P < 0.001), shortening of colon (by 24%; P = 0.016), and histopathology severity score (by 45%; P = 0.01). The YBG group of Expt 2 showed a shift in the abundance of gut microbiota towards Bacteroides (by 16%; P = 0.049) and Verrucomicrobia (mean ± SD: control = 7.8 ± 0.44 vs. YBG = 21.0 ± 9.6%) and a reduction in Firmicutes (by 66%; P < 0.001). The YBG group also showed significantly higher concentrations of fecal SCFAs such as acetic (by 37%; P = 0.016), propionic (by 47%; P = 0.026), and butyric (by 57%; P = 0.013) acids. Compared with controls, the YBG group of Expt 2 showed higher frequencies of Tregs (by 32%; P = 0.043) in the gut mucosa. Depletion of gut microbiota in the YBG group of mice caused diminished fecal SCFA concentrations (Expt 3) and intestinal Treg frequencies (Expt 4). Compared with the YBG group, the YBG-(Abx) group of Expt 5 showed aggravated colitis features including loss of body weight (by >100%; P < 0.01) and colonic inflammation score (by 42%; P = 0.04). Conclusions: Studies using B6 mice show that dietary BGs are beneficial for promoting intestinal health when the gut microbiota is intact. However, these CDPs may produce adverse effects if gut microbiota is compromised. (Copyright © The Author(s) 2019.) |
| References: | J Diet Suppl. 2013 Sep;10(3):171-83. (PMID: 23927572) BMC Gastroenterol. 2012 Apr 16;12:33. (PMID: 22507600) Mucosal Immunol. 2018 May;11(3):763-773. (PMID: 29068000) J Immunol. 2014 Oct 1;193(7):3308-21. (PMID: 25143443) Int J Immunopharmacol. 1989;11(7):761-9. (PMID: 2599714) Nutr Res. 2015 Dec;35(12):1106-12. (PMID: 26500083) Immunology. 2019 May;157(1):70-85. (PMID: 30712258) J Immunol. 2004 Jul 15;173(2):797-806. (PMID: 15240666) Nat Immunol. 2017 May;18(5):552-562. (PMID: 28346408) Diabetes. 2014 Feb;63(2):632-44. (PMID: 24194504) Nat Methods. 2010 May;7(5):335-6. (PMID: 20383131) J Diet Suppl. 2017 Mar 4;14(2):173-185. (PMID: 27715351) Biochem J. 1969 Sep;114(3):557-67. (PMID: 5820642) Nutrients. 2017 Dec 15;9(12):. (PMID: 29244718) Bioinformatics. 2010 Mar 15;26(6):715-21. (PMID: 20130030) Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2247-52. (PMID: 24390544) Yeast. 2000 Apr;17(1):48-55. (PMID: 10928937) J Biol Chem. 2017 Jun 23;292(25):10639-10650. (PMID: 28461332) Cell Rep. 2017 Nov 21;21(8):2277-2290. (PMID: 29166616) Sci Rep. 2019 Aug 19;9(1):12065. (PMID: 31427630) Toxicol Pathol. 2014 Jan;42(1):99-110. (PMID: 24231829) Annu Rev Microbiol. 2017 Sep 8;71:349-369. (PMID: 28657886) Eur J Immunol. 2009 May;39(5):1379-86. (PMID: 19291703) Bioinformatics. 2014 Nov 1;30(21):3123-4. (PMID: 25061070) PLoS One. 2013 Apr 24;8(4):e62016. (PMID: 23637950) Br J Nutr. 2014 May 28;111(10):1822-9. (PMID: 24480400) Int J Immunopharmacol. 1990;12(6):675-84. (PMID: 2272730) PLoS One. 2017 Jul 20;12(7):e0180190. (PMID: 28727837) Science. 2012 Jun 8;336(6086):1314-7. (PMID: 22674328) J Nutr. 2015 Jul;145(7):1415-22. (PMID: 25995281) Nutrition. 2017 Jul - Aug;39-40:30-35. (PMID: 28606567) Clin Exp Immunol. 2015 Aug;181(2):323-37. (PMID: 25703185) J Food Sci. 2016 May;81(5):H1301-8. (PMID: 27074537) J Nutr Metab. 2012;2012:851362. (PMID: 22187640) Anaerobe. 2011 Dec;17(6):403-6. (PMID: 21515398) Appl Environ Microbiol. 2014 Dec;80(24):7551-60. (PMID: 25261516) PLoS One. 2012;7(4):e35314. (PMID: 22536372) Diabetes. 2019 Oct;68(10):1975-1989. (PMID: 31311801) J Crohns Colitis. 2014 Nov;8(11):1464-70. (PMID: 24958064) Gut Microbes. 2012 Jul-Aug;3(4):289-306. (PMID: 22572875) Mycol Res. 2007 Jun;111(Pt 6):635-52. (PMID: 17590323) Gastroenterol Hepatol Bed Bench. 2016 Winter;9(1):45-52. (PMID: 26744614) Nutr J. 2010 Nov 18;9:54. (PMID: 21087484) Biomed Chromatogr. 2006 Aug;20(8):674-82. (PMID: 16206138) Ann Transl Med. 2014 Feb;2(2):17. (PMID: 25332993) Int J Food Sci Nutr. 2015;66(4):355-62. (PMID: 26001090) Curr Allergy Asthma Rep. 2015 May;15(5):24. (PMID: 26139332) Gut Microbes. 2017 Mar 4;8(2):172-184. (PMID: 28165863) Int J Clin Exp Pathol. 2014 Jul 15;7(8):4557-76. (PMID: 25197329) Food Funct. 2015 Nov;6(11):3454-63. (PMID: 26292622) Carbohydr Polym. 2019 Mar 1;207:371-381. (PMID: 30600019) Int J Oncol. 2013 Aug;43(2):357-64. (PMID: 23739801) Physiol Behav. 2008 May 23;94(2):276-84. (PMID: 18222501) Immunity. 2017 Apr 18;46(4):562-576. (PMID: 28423337) World J Gastroenterol. 2016 Jan 21;22(3):1078-87. (PMID: 26811648) Am J Physiol. 1998 Mar;274(3):G544-51. (PMID: 9530156) Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188. (PMID: 28449106) Eur J Immunol. 2008 Feb;38(2):500-6. (PMID: 18200499) Nature. 2013 Dec 19;504(7480):446-50. (PMID: 24226770) World J Gastroenterol. 2017 Sep 7;23(33):6016-6029. (PMID: 28970718) mBio. 2014 Sep 30;5(5):e01548-14. (PMID: 25271284) J Immunol Methods. 2006 Jan 20;308(1-2):251-4. (PMID: 16337223) PLoS One. 2014 Sep 30;9(9):e108794. (PMID: 25268806) Sci Rep. 2017 Sep 13;7(1):11450. (PMID: 28904372) |
| معلومات مُعتمدة: | R21 AI133798 United States AI NIAID NIH HHS; R21 AI136339 United States AI NIAID NIH HHS; R25 GM113278 United States GM NIGMS NIH HHS |
| فهرسة مساهمة: | Keywords: colitis; gut inflammation; gut microbiota; gut mucosa; immune modulation; immune regulation; short-chain fatty acid; yeast β-glucan |
| المشرفين على المادة: | 0 (Fatty Acids, Volatile) 0 (Forkhead Transcription Factors) 0 (Foxp3 protein, mouse) 0 (Polysaccharides) 0 (beta-Glucans) 147336-22-9 (Green Fluorescent Proteins) 9042-14-2 (Dextran Sulfate) |
| تواريخ الأحداث: | Date Created: 20191228 Date Completed: 20200914 Latest Revision: 20230216 |
| رمز التحديث: | 20230216 |
| مُعرف محوري في PubMed: | PMC7198290 |
| DOI: | 10.1093/jn/nxz328 |
| PMID: | 31879786 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1541-6100 |
|---|---|
| DOI: | 10.1093/jn/nxz328 |